Estetrol
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329498

CAS#: 15183-37-6

Description: Estetrol is is a potent, orally bioavailable, natural human fetal selective estrogen receptor modulator, since it acts in the rat as an estrogen on all tissues investigated except breast tumor tissue, where it has estrogen antagonistic properties in the presence of estradiol. Estetrol attenuates neonatal hypoxic-ischemic brain injury. Estetrol may be suitable as a potential drug for human use in applications such as hormone replacement therapy (vaginal atrophy, hot flushes), contraception and osteoporosis. Additional areas worth exploring are the treatment of breast and prostate cancer, hypoactive sexual desire disorder and topical use.

Chemical Structure

img
Estetrol
CAS# 15183-37-6
Instruction

Theoretical Analysis

MedKoo Cat#: 329498
Name: Estetrol
CAS#: 15183-37-6
Chemical Formula: C18H24O4
Exact Mass: 304.17
Molecular Weight: 304.386
Elemental Analysis: C, 71.03; H, 7.95; O, 21.02

Price and Availability

Size Price Availability Quantity
5mg USD 550 2 Weeks
25mg USD 1650 2 Weeks
50mg USD 2950 2 Weeks
100mg USD 5250 2 Weeks
Bulk inquiry

Synonym: Estetrol; E4; 15α-Hydroxyestriol; ENB 39R14VF; ENB-39R14VF; ENB39R14VF;

IUPAC/Chemical Name: (8R,9S,13S,14S,15R,16R,17R)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,15,16,17-tetraol

InChi Key: AJIPIJNNOJSSQC-NYLIRDPKSA-N

InChi Code: InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1

SMILES Code: OC1=CC(CC[C@]2([H])[C@]3([H])CC[C@@]4(C)[C@@]2([H])[C@@H](O)[C@@H](O)[C@@H]4O)=C3C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 304.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gaspard U, Taziaux M, Jost M, Coelingh Bennink HJT, Utian WH, Lobo RA, Foidart JM. A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life. Menopause. 2023 Feb 21. doi: 10.1097/GME.0000000000002167. Epub ahead of print. PMID: 36809193.


2: Gemzell-Danielsson Kristina, Cagnacci Angelo, Chabbert-Buffet Nathalie, Douxfils Jonathan, Foidart Jean-Michel, Kubba Ali, Lasa Luis Ignacio Lete, Mansour Diana, Neulen Joseph, Neves Jaoquim, Palma Fátima, Römer Thomas, Ski Robert Spaczy, Tóth Vera. A novel estetrol-containing combined oral contraceptive: European expert panel review. Ceska Gynekol. 2022;87(6):440-452. English. PMID: 36543594.


3: Douxfils J, Gaspard U, Taziaux M, Jost M, Bouvy C, Lobo RA, Utian WH, Foidart JM. Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. Climacteric. 2023 Feb;26(1):55-63. doi: 10.1080/13697137.2022.2139599. Epub 2022 Nov 18. PMID: 36399023.


4: Zimmerman Y, Frydenberg M, van Poppel H, van Moorselaar RJA, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Krijgh J, Debruyne FMJ, Coelingh Bennink HJT. Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study. Eur Urol Open Sci. 2022 Oct 3;45:59-67. doi: 10.1016/j.euros.2022.09.006. PMID: 36353657; PMCID: PMC9637725.


5: Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Zatik J, Weyers S, Piltonen T, Suturina L, Apolikhina I, Bouchard C, Archer DF, Jost M, Foidart JM, Creinin M. Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. Contraception. 2022 Dec;116:44-50. doi: 10.1016/j.contraception.2022.10.004. Epub 2022 Oct 17. PMID: 36257374.


6: Douxfils J, Morimont L, Gaspard U, Utian WH, Foidart JM. Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation. Thromb Res. 2022 Sep 16:S0049-3848(22)00387-5. doi: 10.1016/j.thromres.2022.09.007. Epub ahead of print. PMID: 36130859.


7: Morimont L, Jost M, Gaspard U, Foidart JM, Dogné JM, Douxfils J. Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone. J Clin Endocrinol Metab. 2022 Dec 17;108(1):135-143. doi: 10.1210/clinem/dgac511. PMID: 36099501; PMCID: PMC9759169.


8: Lee A, Syed YY. Correction: Estetrol/Drospirenone: A Review in Oral Contraception. Drugs. 2022 Aug;82(12):1341. doi: 10.1007/s40265-022-01760-w. Erratum for: Drugs. 2022 Jul;82(10):1117-1125. PMID: 35945474; PMCID: PMC9499896.


9: Kaunitz AM, Achilles SL, Zatik J, Weyers S, Piltonen T, Suturina L, Apolikhina I, Bouchard C, Chen MJ, Jensen JT, Westhoff CL, Jost M, Foidart JM, Creinin MD. Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women. Contraception. 2022 Dec;116:29-36. doi: 10.1016/j.contraception.2022.07.010. Epub 2022 Aug 1. PMID: 35921872.


10: Jensen JT, Kaunitz AM, Achilles SL, Zatik J, Weyers S, Piltonen T, Suturina L, Apolikhina I, Bouchard C, Chen MJ, Apter D, Jost M, Foidart JM, Creinin MD. Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials. Contraception. 2022 Dec;116:37-43. doi: 10.1016/j.contraception.2022.07.009. Epub 2022 Jul 31. PMID: 35921870.


11: Gemzell-Danielsson K, Cagnacci A, Chabbert-Buffet N, Douxfils J, Foidart JM, Kubba A, Lete Lasa LI, Mansour D, Neulen J, Neves J, Palma F, Römer T, Spaczyński R, Tóth V. A novel estetrol-containing combined oral contraceptive: European expert panel review. Eur J Contracept Reprod Health Care. 2022 Oct;27(5):373-383. doi: 10.1080/13625187.2022.2093850. Epub 2022 Jul 21. PMID: 35862627.


12: Lee A, Syed YY. Estetrol/Drospirenone: A Review in Oral Contraception. Drugs. 2022 Jul;82(10):1117-1125. doi: 10.1007/s40265-022-01738-8. Epub 2022 Jul 4. Erratum in: Drugs. 2022 Aug;82(12):1341. PMID: 35781795; PMCID: PMC9363382.


13: Gérard C, Arnal JF, Jost M, Douxfils J, Lenfant F, Fontaine C, Houtman R, Archer DF, Reid RL, Lobo RA, Gaspard U, Coelingh Bennink HJT, Creinin MD, Foidart JM. Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Rev Clin Pharmacol. 2022 Feb;15(2):121-137. doi: 10.1080/17512433.2022.2054413. Epub 2022 Mar 27. PMID: 35306927.


14: Paton DM. Estetrol and drospirenone: a novel oral contraceptive. Drugs Today (Barc). 2022 Jan;58(1):1-8. doi: 10.1358/dot.2022.58.1.3353167. PMID: 35107089.


15: Fruzzetti F, Fidecicchi T, Montt Guevara MM, Simoncini T. Estetrol: A New Choice for Contraception. J Clin Med. 2021 Nov 29;10(23):5625. doi: 10.3390/jcm10235625. PMID: 34884326; PMCID: PMC8658652.


16: Gallez A, Dias Da Silva I, Wuidar V, Foidart JM, Péqueux C. Estetrol and Mammary Gland: Friends or Foes? J Mammary Gland Biol Neoplasia. 2021 Sep;26(3):297-308. doi: 10.1007/s10911-021-09497-0. Epub 2021 Aug 31. PMID: 34463898; PMCID: PMC8566418.


17: Coelingh Bennink HJT, van Moorselaar JA, Crawford ED, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Zimmerman Y, van Osta G, Krijgh J, Shore ND, Saad F, Schally AV, Debruyne FMJ. Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi). Eur Urol Open Sci. 2021 May 6;28:52-61. doi: 10.1016/j.euros.2021.04.005. PMID: 34337526; PMCID: PMC8317802.


18: Gemzell-Danielsson K, Apter D, Zatik J, Weyers S, Piltonen T, Suturina L, Apolikhina I, Jost M, Creinin MD, Foidart JM. Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022 Jan;129(1):63-71. doi: 10.1111/1471-0528.16840. Epub 2021 Aug 9. PMID: 34245666; PMCID: PMC9290720.


19: Estetrol/drospirenone (Nextstellis) - a new combination oral contraceptive. Med Lett Drugs Ther. 2021 Jun 28;63(1627):101-102. PMID: 34181632.


20: Křepelka Petr. Estetrol and the possibilities of its clinical use. Ceska Gynekol. 2021;86(3):217-221. English. doi: 10.48095/cccg2021217. PMID: 34167315.